Lamictal Dosing Illustrator
 
LAMICTAL Dosing Illustrator

IMPORTANT SAFETY INFORMATION
Cases of life-threatening serious rashes, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and/or rash-related death, have been caused by LAMICTAL. (See Boxed Warning). CONTINUED BELOW
Prescribing Information, including Boxed Warning and Medication Guide.
 
Patient's Name
(first name, last name)
 
Age (in years)
•  
Weight
 •
  lbs kg 
    Age/Weight Table Used in this Calculation
    For complete information, please refer to current dosing
and administration in the Prescribing Information.
Therapy
 •
LAMICTAL added to carbamazepine, phenytoin,
phenobarbital or primidone* (without valproate [VPA]†)
LAMICTAL added to any AED regimen containing VPA†  
LAMICTAL added to other AED regimens NOT
containing carbamazepine, phenytoin, phenobarbital
or primidone* and NOT containing VPA†  
 
Start Date
• If you would like to change the date, click here:  
GlaxoSmithKline does not collect or maintain patient-specific
information from this Web site.
  *These drugs induce lamotrigine glucuronidation and increase clearance. Other drugs
which have similar effects include estrogen-containing oral contraceptives and rifampin.
Patients on these drugs, or other drugs that induce lamotrigine glucuronidation and increase
clearance, should follow the same dosing titration/maintenance regimen as that used with
anticonvulsants that have this effect.
†Valproate (VPA) has been shown to inhibit glucuronidation and decrease the apparent clearance of lamotrigine.
 
Initial Target Maintenance Dose of LAMICTAL
Recommended Range:
 • mg per kg per day
Dosage Increase Increment
(after first 4 weeks)
 •  
Dosage Increase Frequency
(after first 4 weeks)
•  
Choose
 • Healthcare Provider's version
Patient's version
 
     
Calculated dosages are rounded down to the nearest 5-mg tablet for patients weighing 14 kg (31 lbs) and over, and rounded down to the nearest 2-mg tablet for patients under 14 kg.
  • Required Fields
    DISCLAIMER OF LIABILITY: GlaxoSmithKline makes no warranties, expressed or implied, with respect to the Dosing Illustrator for LAMICTAL. ALL WARRANTIES, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF QUALITY, ACCURACY, MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE, ARE HEREBY DISCLAIMED BY GLAXOSMITHKLINE. In no event will GlaxoSmithKline be liable for any special, incidental, or consequential damages resulting from the use of the Dosing Illustrator for LAMICTAL.
 

Important Safety Information for LAMICTAL Tablets

BOXED WARNING: SERIOUS SKIN RASHES

See full Prescribing Information for complete Boxed Warning.

Cases of life-threatening serious rashes, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and/or rash-related death, have been caused by LAMICTAL. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:

  • coadministration with valproate
  • exceeding recommended initial dose of LAMICTAL
  • exceeding recommended dose escalation of LAMICTAL

Benign rashes are also caused by LAMICTAL; however, it is not possible to predict which rashes will prove to be serious or life-threatening. LAMICTAL should be discontinued at the first sign of rash, unless the rash is clearly not drug-related.

  • Hypersensitivity reaction may be fatal or life-threatening. Early signs of hypersensitivity (eg, fever, lymphadenopathy) may present without rash; if signs present, patient should be evaluated immediately. LAMICTAL should be discontinued if alternate etiology for hypersensitivity signs is not found.
  • Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (eg, fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately.
  • Acute multiorgan failure has resulted (some cases fatal).
  • Blood dyscrasias (eg, neutropenia, thrombocytopenia, pancytopenia) may result either with or without an associated hypersensitivity syndrome.
  • Antiepileptic drugs, including LAMICTAL, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.
  • Patients treated with any antiepileptic drug for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
  • Patients, their caregivers, and families should be informed that antiepileptic drugs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

Please consult complete Prescribing Information for LAMICTAL, including Boxed Warning.

 
This website is funded and developed by GlaxoSmithKline.
This site is intended for US healthcare professionals only.
© 1997-2010 GlaxoSmithKline. All Rights Reserved.
Legal Notices | Privacy Statement | Medicine Savings | Contact Us